Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial, The Lancet Respiratory Medicine

In this RCT (n=400), imatinib (800mg load followed by 400mg daily on days 1-9) did not reduce the time to discontinuation of ventilation and supplemental oxygen for more than 48 consecutive hours in patients with COVID-19 requiring supplemental oxygen.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news